Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

AACR 2017

1 - 5 Apr 2017

Walter E. Washington Convention Center, Washington, D.C., United States of America

AACR 2017: Rice bran adds microbiome diversity, slows growth of colon cancer cells

AACR 2017: Rice bran adds microbiome diversity, slows growth of colon cancer cells

AACR 2017: Five year survival rates for nivolumab to treat relapsed NSCLC

AACR 2017: Five year survival rates for nivolumab to treat relapsed NSCLC

AACR 2017: Patients' immune system may influence effectiveness of cancer immunotherapy

AACR 2017: Patients' immune system may influence effectiveness of cancer immunotherapy

AACR 2017: Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

AACR 2017: Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

AACR 2017: New imaging of PARP activity in ovarian cancer

AACR 2017: New imaging of PARP activity in ovarian cancer

AACR 2017: New therapeutic shows pre-clinical efficacy against castration resistant prostate cancer

AACR 2017: New therapeutic shows pre-clinical efficacy against castration resistant prostate cancer

AACR 2017: Cancer burden may be changing for people living with HIV

AACR 2017: Cancer burden may be changing for people living with HIV

AACR 2017: Mechanism of PD-1/lenvatinib combo exposed, improving CR in mouse models

AACR 2017: Mechanism of PD-1/lenvatinib combo exposed, improving CR in mouse models

AACR 2017: PD-1/virus combination shows promise for advanced melanoma

AACR 2017: PD-1/virus combination shows promise for advanced melanoma

AACR 2017: IDH-mutant cancers may be more amenable to PARP inhibition than IDH inhibition

AACR 2017: IDH-mutant cancers may be more amenable to PARP inhibition than IDH inhibition

AACR 2017: Adding IDO inhibition to pembrolizumab improved response rate in melanoma

AACR 2017: Adding IDO inhibition to pembrolizumab improved response rate in melanoma

AACR 2017: Regular aspirin use is associated with lower cancer mortality

AACR 2017: Regular aspirin use is associated with lower cancer mortality

AACR 2017: Deploying anti-bacterial immune responses to kill cancer

AACR 2017: Deploying anti-bacterial immune responses to kill cancer

AACR 2017: Shorter sleep duration is associated with increased risk of prostate cancer in younger men

AACR 2017: Shorter sleep duration is associated with increased risk of prostate cancer in younger men

AACR 2017: Avelumab was safe and yielded durable responses for patients with advanced merkel cell carcinoma

AACR 2017: Avelumab was safe and yielded durable responses for patients with advanced merkel cell carcinoma

AACR 2017: Triple-negative breast cancer patients who responded to immunotherapy had long-term survival benefit

AACR 2017: Triple-negative breast cancer patients who responded to immunotherapy had long-term survival benefit

AACR 2017: Combination of nivolumab and ipilimumab improved overall survival for advanced melanoma patients

AACR 2017: Combination of nivolumab and ipilimumab improved overall survival for advanced melanoma patients

AACR 2017: Biomarker may identify neuroblastoma patients most likely to benefit from immunotherapy

AACR 2017: Biomarker may identify neuroblastoma patients most likely to benefit from immunotherapy

AACR 2017: New gene-based blood tests identify more skin cancers

AACR 2017: New gene-based blood tests identify more skin cancers

AACR 2017: HER2/3 influence neratinib response in basket clinical trial

AACR 2017: HER2/3 influence neratinib response in basket clinical trial

AACR 2017: Combination HER2-targeted therapy effective in heavily pretreated HER2 positive colorectal cancer patients

AACR 2017: Combination HER2-targeted therapy effective in heavily pretreated HER2 positive colorectal cancer...

AACR 2017: Wearable medical device improves survival for patients with glioblastoma

AACR 2017: Wearable medical device improves survival for patients with glioblastoma

AACR 2017: Protein identified as potential druggable target for pancreatic cancer

AACR 2017: Protein identified as potential druggable target for pancreatic cancer

More from ecancer